Published in Curr HIV/AIDS Rep on June 01, 2005
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS (2002) 2.59
Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J Pharm Biomed Anal (2011) 2.10
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr (2002) 1.98
Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS (2009) 1.95
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses (2012) 1.89
Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.78
Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses (2003) 1.67
Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses (2002) 1.66
Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS (2002) 1.58
Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis (2004) 1.53
Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. J Acquir Immune Defic Syndr (2005) 1.52
Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. J Acquir Immune Defic Syndr (2004) 1.48
Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr (2008) 1.43
Review and management of drug interactions with boceprevir and telaprevir. Hepatology (2012) 1.42
Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr (2008) 1.24
Quantitation of zidovudine triphosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography-tandem mass spectroscopy; an indirect quantitation methodology. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.16
Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr (2009) 1.11
Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet (2002) 1.11
Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS. J Pharm Biomed Anal (2013) 1.11
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemother (2010) 1.06
Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. J Acquir Immune Defic Syndr (2014) 1.05
Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence. J Pharmacokinet Pharmacodyn (2006) 1.05
The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850). J Infect Dis (2002) 1.01
Atazanavir-containing renal calculi in an HIV-infected patient. AIDS (2007) 1.01
Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. J Acquir Immune Defic Syndr (2014) 1.00
Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother (2007) 0.98
Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures. J Acquir Immune Defic Syndr (2015) 0.96
The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing. J Acquir Immune Defic Syndr (2005) 0.94
Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther (2005) 0.93
Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. AIDS (2006) 0.90
A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. HIV Clin Trials (2011) 0.89
Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women. AIDS Res Hum Retroviruses (2014) 0.87
Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substrates. Chirality (2004) 0.87
A population pharmacokinetic-pharmacogenetic analysis of atazanavir. AIDS Res Hum Retroviruses (2012) 0.86
Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther (2006) 0.84
Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals. J Acquir Immune Defic Syndr (2015) 0.84
Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessment. Drug Metab Dispos (2010) 0.83
Clinical pharmacokinetics of antiretroviral drugs in older persons. Expert Opin Drug Metab Toxicol (2013) 0.83
CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. AIDS (2004) 0.82
Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy (2006) 0.81
Validation of a sensitive LC/MS/MS method for the determination of zidovudine and lamivudine in human plasma. Biomed Chromatogr (2011) 0.81
Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin. J Clin Pharmacol (2011) 0.81
Characterization of HIV seroconverters in a TDF/FTC PrEP study: HPTN 067/ADAPT. J Acquir Immune Defic Syndr (2017) 0.80
Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine. Antimicrob Agents Chemother (2012) 0.79
A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring. AIDS (2016) 0.79
Effect of nucleoside and nucleotide analog reverse transcriptase inhibitors on cell-mediated immune functions. AIDS Res Hum Retroviruses (2010) 0.78
Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy. AIDS (2005) 0.77
Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects. Pharmacotherapy (2009) 0.77
Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. J Antimicrob Chemother (2006) 0.77
Determination of the absolute configuration and solution conformation of the antifungal agents ketoconazole, itraconazole, and miconazole with vibrational circular dichroism. Chirality (2005) 0.76
PharmGKB summary: zidovudine pathway. Pharmacogenet Genomics (2012) 0.76
Editorial comment: drug-drug interactions, hepatitis C, and mitochondrial toxicity. AIDS Read (2003) 0.76
Changes in Kidney Function Associated with Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project. J Acquir Immune Defic Syndr (2017) 0.75
Recovery of Bone Mineral Density Following Discontinuation of Tenofovir-Based HIV Pre-Exposure Prophylaxis. J Acquir Immune Defic Syndr (2017) 0.75
Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users. AIDS (2017) 0.75
Validation of a sensitive LC/MS/MS method for the determination of telaprevir and its R-isomer in human plasma. Biomed Chromatogr (2014) 0.75
Stereoselective determination of the epimer mixtures of itraconazole in human blood plasma using HPLC and fluorescence detection. Chirality (2011) 0.75
Newly Acquired Infection with Multi-Drug Resistant HIV-1 in a Patient Adherent to Pre-Exposure Prophylaxis. J Acquir Immune Defic Syndr (2017) 0.75
Plasma Tenofovir-levels to Support Adherence to TDF/FTC Pre-exposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California. J Acquir Immune Defic Syndr (2017) 0.75
The ABC's of pharmacokinetics. Posit Aware (2005) 0.75
6th International Workshop on Clinical Pharmacology of HIV Therapy. Expert Opin Pharmacother (2006) 0.75
Adherence biomarker measurements in older and younger HIV-infected adults receiving tenofovir-based therapy. J Acquir Immune Defic Syndr (2017) 0.75
Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis. J Acquir Immune Defic Syndr (2017) 0.75
Abacavir pharmacokinetics in hepatic dysfunction. Clin Infect Dis (2005) 0.75
Hair Levels of PrEP Drugs Measure Adherence and are Associated with Renal Decline Among Men/Transwomen in an Open Label PrEP Study. AIDS (2017) 0.75
Multiplex PCR-pyrosequencing assay for genotyping CYP3A5 polymorphisms. Clin Chim Acta (2006) 0.75